You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for SC 58125
SC 58125 is a selective cyclooxygenase 2 (COX-2) inhibitor (IC50 values are 0.04 and >100 μM for COX-2 and COX-1 respectively). Anti-inflammatory; blocks edema and hyperalgesia in vivo following an inflammatory insult, without causing gastric mucosal damage. Also displays antitumor activity.
Sold for research purposes under agreement from Pfizer Inc.
Technical Data for SC 58125
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for SC 58125
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for SC 58125
The following data is based on the product molecular weight 384.35. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.6 mL||13.01 mL||26.02 mL|
|5 mM||0.52 mL||2.6 mL||5.2 mL|
|10 mM||0.26 mL||1.3 mL||2.6 mL|
|50 mM||0.05 mL||0.26 mL||0.52 mL|
References for SC 58125
References are publications that support the biological activity of the product.
Gierse et al (1996) A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J.Biol.Chem. 271 15810 PMID: 8663121
Williams et al (2001) A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established colon cancer xenografts. Neoplasia 3 428 PMID: 11687954
Seibert et al (1994) Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc.Natl.Acad.Sci.USA 91 12013
If you know of a relevant reference for SC 58125, please let us know.
View Related Products by Product Action
Keywords: SC 58125, SC 58125 supplier, Selective, cyclooxygenase-2, COX-2, inhibitors, inhibits, Oxygenases, Oxidases, SC58125, Pfizer, Cyclooxygenase, 2895, Tocris Bioscience
1 Citation for SC 58125
Citations are publications that use Tocris products. Selected citations for SC 58125 include:
Lee et al (2018) CCL17 blockade as a therapy for osteoarthritis pain and disease. Arthritis Res Ther 20 62 PMID: 29622035
Do you know of a great paper that uses SC 58125 from Tocris? Please let us know.
Reviews for SC 58125
There are currently no reviews for this product. Be the first to review SC 58125 and earn rewards!
Have you used SC 58125?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.